Last reviewed · How we verify

TiGenix n.v. — Portfolio Competitive Intelligence Brief

TiGenix n.v. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
ChondroCelect implantation ChondroCelect implantation phase 3 Autologous cell therapy Orthopedics / Rheumatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Cook MyoSite · 1 shared drug class
  2. GC Cell Corporation · 1 shared drug class
  3. Seoul National University Bundang Hospital · 1 shared drug class
  4. Sewon Cellontech Co., Ltd. · 1 shared drug class
  5. StemCyte, Inc. · 1 shared drug class
  6. Tetec AG · 1 shared drug class
  7. UnicoCell Biomed CO. LTD · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for TiGenix n.v.:

Cite this brief

Drug Landscape (2026). TiGenix n.v. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tigenix-n-v. Accessed 2026-06-10.

Related